Embecta (EMBC) Competitors

$3.32 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$3.33 +0.01 (+0.42%)

As of 05/22/2026 07:30 PM Eastern

EMBC vs. SIBN, CBLL, BWAY, TCMD, and NPCE

Should you buy Embecta stock or one of its competitors? MarketBeat compares Embecta with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Embecta include SiBone (SIBN), CeriBell (CBLL), Brainsway (BWAY), Tactile Systems Technology (TCMD), and NeuroPace (NPCE). These companies are all part of the "medical equipment" industry.

How does Embecta compare to SiBone?

SiBone (NASDAQ:SIBN) and Embecta (NASDAQ:EMBC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

Embecta has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	3.24	-$18.90M	-$0.39	N/A
Embecta	$1.08B	0.18	$95.40M	$1.90	1.75

SiBone presently has a consensus price target of $23.00, suggesting a potential upside of 56.68%. Embecta has a consensus price target of $11.00, suggesting a potential upside of 231.33%. Given Embecta's higher possible upside, analysts clearly believe Embecta is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Embecta	3 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.40

98.1% of SiBone shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 4.0% of SiBone shares are held by insiders. Comparatively, 1.3% of Embecta shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Embecta has a net margin of 10.73% compared to SiBone's net margin of -8.10%. SiBone's return on equity of -9.56% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
Embecta	10.73%	-23.96%	14.12%

SiBone has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Embecta has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market.

In the previous week, SiBone and SiBone both had 4 articles in the media. Embecta's average media sentiment score of -0.27 beat SiBone's score of -0.70 indicating that Embecta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Embecta	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Embecta beats SiBone on 9 of the 15 factors compared between the two stocks.

How does Embecta compare to CeriBell?

Embecta (NASDAQ:EMBC) and CeriBell (NASDAQ:CBLL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

Embecta has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.18	$95.40M	$1.90	1.75
CeriBell	$89.06M	8.00	-$53.41M	-$1.63	N/A

Embecta has a net margin of 10.73% compared to CeriBell's net margin of -63.51%. Embecta's return on equity of -23.96% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	10.73%	-23.96%	14.12%
CeriBell	-63.51%	-38.19%	-30.92%

Embecta has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, CeriBell has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market.

93.8% of Embecta shares are held by institutional investors. 1.3% of Embecta shares are held by insiders. Comparatively, 20.1% of CeriBell shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Embecta had 2 more articles in the media than CeriBell. MarketBeat recorded 4 mentions for Embecta and 2 mentions for CeriBell. CeriBell's average media sentiment score of 0.20 beat Embecta's score of -0.27 indicating that CeriBell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Embecta	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
CeriBell	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Embecta currently has a consensus target price of $11.00, indicating a potential upside of 231.33%. CeriBell has a consensus target price of $22.20, indicating a potential upside of 18.27%. Given Embecta's higher probable upside, research analysts clearly believe Embecta is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	3 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.40
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Embecta beats CeriBell on 11 of the 17 factors compared between the two stocks.

How does Embecta compare to Brainsway?

Brainsway (NASDAQ:BWAY) and Embecta (NASDAQ:EMBC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

Brainsway has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market. Comparatively, Embecta has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

Brainsway has a net margin of 15.68% compared to Embecta's net margin of 10.73%. Brainsway's return on equity of 12.28% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainsway	15.68%	12.28%	7.75%
Embecta	10.73%	-23.96%	14.12%

In the previous week, Embecta had 3 more articles in the media than Brainsway. MarketBeat recorded 4 mentions for Embecta and 1 mentions for Brainsway. Brainsway's average media sentiment score of 0.00 beat Embecta's score of -0.27 indicating that Brainsway is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainsway	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Embecta	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

30.1% of Brainsway shares are owned by institutional investors. Comparatively, 93.8% of Embecta shares are owned by institutional investors. 19.0% of Brainsway shares are owned by company insiders. Comparatively, 1.3% of Embecta shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Embecta has higher revenue and earnings than Brainsway. Embecta is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainsway	$52.22M	11.58	$7.57M	$0.35	43.14
Embecta	$1.08B	0.18	$95.40M	$1.90	1.75

Brainsway presently has a consensus target price of $15.00, indicating a potential downside of 0.66%. Embecta has a consensus target price of $11.00, indicating a potential upside of 231.33%. Given Embecta's higher probable upside, analysts plainly believe Embecta is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Embecta	3 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.40

Summary

Brainsway beats Embecta on 9 of the 16 factors compared between the two stocks.

How does Embecta compare to Tactile Systems Technology?

Embecta (NASDAQ:EMBC) and Tactile Systems Technology (NASDAQ:TCMD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

Embecta has higher revenue and earnings than Tactile Systems Technology. Embecta is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.18	$95.40M	$1.90	1.75
Tactile Systems Technology	$329.52M	1.70	$19.09M	$0.88	28.30

93.8% of Embecta shares are held by institutional investors. Comparatively, 83.4% of Tactile Systems Technology shares are held by institutional investors. 1.3% of Embecta shares are held by insiders. Comparatively, 2.1% of Tactile Systems Technology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Embecta has a net margin of 10.73% compared to Tactile Systems Technology's net margin of 5.91%. Tactile Systems Technology's return on equity of 9.70% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	10.73%	-23.96%	14.12%
Tactile Systems Technology	5.91%	9.70%	7.53%

Embecta has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Tactile Systems Technology has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market.

In the previous week, Tactile Systems Technology had 3 more articles in the media than Embecta. MarketBeat recorded 7 mentions for Tactile Systems Technology and 4 mentions for Embecta. Tactile Systems Technology's average media sentiment score of 0.39 beat Embecta's score of -0.27 indicating that Tactile Systems Technology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Embecta	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tactile Systems Technology	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Embecta presently has a consensus price target of $11.00, indicating a potential upside of 231.33%. Tactile Systems Technology has a consensus price target of $38.60, indicating a potential upside of 55.02%. Given Embecta's higher probable upside, equities analysts plainly believe Embecta is more favorable than Tactile Systems Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	3 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.40
Tactile Systems Technology	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Tactile Systems Technology beats Embecta on 9 of the 17 factors compared between the two stocks.

How does Embecta compare to NeuroPace?

Embecta (NASDAQ:EMBC) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Embecta has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, NeuroPace has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market.

Embecta presently has a consensus price target of $11.00, suggesting a potential upside of 231.33%. NeuroPace has a consensus price target of $18.83, suggesting a potential upside of 11.31%. Given Embecta's higher probable upside, equities research analysts clearly believe Embecta is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	3 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.40
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Embecta has a net margin of 10.73% compared to NeuroPace's net margin of -21.67%. Embecta's return on equity of -23.96% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	10.73%	-23.96%	14.12%
NeuroPace	-21.67%	-108.20%	-18.50%

In the previous week, NeuroPace had 2 more articles in the media than Embecta. MarketBeat recorded 6 mentions for NeuroPace and 4 mentions for Embecta. NeuroPace's average media sentiment score of 0.51 beat Embecta's score of -0.27 indicating that NeuroPace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Embecta	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeuroPace	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

93.8% of Embecta shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 1.3% of Embecta shares are held by company insiders. Comparatively, 20.5% of NeuroPace shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Embecta has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.18	$95.40M	$1.90	1.75
NeuroPace	$99.99M	5.77	-$21.47M	-$0.65	N/A

Summary

Embecta beats NeuroPace on 9 of the 17 factors compared between the two stocks.

Get Embecta News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EMBC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EMBC vs. The Competition

Export

Metric	Embecta	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$196.97M	$8.38B	$6.46B	$12.34B
Dividend Yield	18.07%	2.98%	2.76%	5.28%
P/E Ratio	1.75	21.27	21.00	25.66
Price / Sales	0.18	19.11	558.19	86.31
Price / Cash	0.83	86.20	43.49	56.67
Price / Book	-0.31	5.84	10.40	7.14
Net Income	$95.40M	$183.47M	$3.57B	$335.98M
7 Day Performance	14.48%	64.18%	6.40%	4.11%
1 Month Performance	-63.99%	49.96%	3.55%	2.52%
1 Year Performance	-69.03%	4.53%	34.13%	35.04%

Embecta Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
EMBC Embecta	4.004 of 5 stars	$3.32 flat	$11.00 +231.3%	-69.0%	$196.97M	$1.08B	1.75	1,850
SIBN SiBone	2.3468 of 5 stars	$14.87 +0.7%	$23.00 +54.7%	-20.1%	$658.46M	$200.93M	N/A	350
CBLL CeriBell	1.9473 of 5 stars	$16.68 +0.6%	$22.20 +33.1%	+13.2%	$633.37M	$89.06M	N/A	N/A
BWAY Brainsway	1.8306 of 5 stars	$14.54 -2.3%	$15.00 +3.2%	+181.5%	$582.78M	$52.22M	41.59	120
TCMD Tactile Systems Technology	4.017 of 5 stars	$24.13 +2.0%	$38.60 +59.9%	+164.3%	$546.63M	$329.52M	27.53	1,086

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EMBC) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Embecta (EMBC) Competitors